RoosterBio Partners with Thermo Fisher to Enhance Manufacturing of Cell and Exosome Therapies

RoosterBio and Thermo Fisher Scientific: A New Era in Cell Therapy Manufacturing

In a significant advancement for regenerative medicine, RoosterBio, Inc. has announced its collaboration with Thermo Fisher Scientific, a global powerhouse in the scientific arena. This strategic partnership is geared towards accelerating the development and manufacturing of cell and exosome therapies, which hold the promise of transforming treatment options for individuals suffering from degenerative diseases.

Uniting Forces for Innovation

RoosterBio has established itself as a premier supplier of adult human mesenchymal stem/stromal cells (hMSCs), as well as a provider of specialized media and bioprocess development. Their products have been critical in yielding new therapeutic solutions. On the other hand, Thermo Fisher Scientific brings to the table its extensive expertise in Good Manufacturing Practices (GMP) and contract manufacturing, forming a potent alliance aimed at transforming how these therapies are developed and manufactured.

The collaboration will specifically leverage RoosterBio's extensive portfolio of hMSC products and processes alongside Thermo Fisher's refined GMP capabilities. This combination is set to create a comprehensive framework for biopharmaceutical companies looking to expedite clinical trial materials' availability. The partnership ensures that these companies can access a robust solution for their development and manufacturing needs.

Streamlining the Manufacturing Process

The collaboration will enable the following services:
1. Upstream Expansion of hMSCs: This involves growing and expanding the stem cells necessary for therapeutic applications.
2. Downstream Purification: This step focuses on extracting and purifying the MSCs and their derivatives, including exosomes, which are crucial in numerous treatment regimens.
3. Drug Product Manufacturing: The final stages of creating therapeutic products ready for clinical trials and potential market release.

Tim Kelly, CEO of RoosterBio, emphasized the importance of this partnership by stating, "Thermo Fisher has an exceptional track record of success in the manufacture of clinical and commercial cell and gene therapies... Through this collaboration, we will deliver that comprehensive solution to our customers."

A Commitment to Safety and Efficacy

Both RoosterBio and Thermo Fisher share a commitment to bioethics and the highest standards of safety and efficacy. RoosterBio sources its hMSCs under stringent guidelines and employs highly standardized production processes, which is crucial in maintaining the integrity of their therapeutic offerings.

Ben Castro, Vice President and General Manager at Thermo Fisher, further noted, "Our collaboration with RoosterBio reflects our shared commitment to helping life-changing therapies reach patients in need..." This shared mission illustrates the steadfast dedication of both organizations to provide new solutions to those who need them most.

Looking Toward the Future

As the landscape of regenerative medicine continues to evolve, partnerships like the one between RoosterBio and Thermo Fisher will play an essential role in bringing innovative therapies to life. By combining their resources and expertise, they aim to shorten the pathway from lab to clinic, making groundbreaking treatments accessible to patients faster than ever before.

The ultimate goal is clear: to foster an environment where regenerative therapies can flourish, ultimately enhancing the quality and longevity of lives impacted by degenerative diseases. As we watch this partnership develop, the medical community remains hopeful about the potential advancements in treatment options for patients globally.

For more information about RoosterBio and their groundbreaking work in stem cell therapy, visit RoosterBio's official website.